SCHEMBL10003604

SCHEMBL10003604

CCc1nc2c(cc1Nc1cccc(OC)c1)c(OCC(F)(F)F)c(C(=O)O)n2C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKR1C3 P42330 3/20 0.41
▸ AKR1C2 P52895 3/20 0.41
▸ CYP1A2 P05177 3/20 0.40
▸ USP2 O75604 2/20 0.40
▸ CYP2C19 P33261 2/20 0.40
▸ GAK O14976 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CLK4 Q9HAZ1 1/20 0.40
▸ CNR2 P34972 1/20 0.40
▸ HTT P42858 2/20 0.39
▸ TSHR P16473 1/20 0.39
▸ ALPL P05186 1/20 0.39
▸ ALPI P09923 1/20 0.39
▸ CSNK2A2 P19784 1/20 0.39
▸ CSNK2B P67870 1/20 0.39
▸ CSNK2A1 P68400 1/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10003100 0.91 CDC25B (0.47) CYP1A2USP2CYP2C19GAKCYP3A4
SCHEMBL10003601 0.91 ATM (0.39) AKR1C3AKR1C2CNR2MEN1KMT2A
SCHEMBL10003245 0.90 MEN1 (0.38) HTTMEN1KMT2AGAAPDE4A
SCHEMBL10003818 0.89 MEN1 (0.38) AKR1C3AKR1C2CYP1A2CYP2C19CYP3A4
SCHEMBL10003992 0.87 CNR2 (0.39) AKR1C3AKR1C2CNR2MEN1KMT2A
SCHEMBL10003518 0.84 RORC (0.38) AKR1C3AKR1C2MEN1KMT2A
SCHEMBL10003394 0.83 GRIA2 (0.43) AKR1C3AKR1C2HSD17B10
SCHEMBL10003550 0.83 PPARG (0.40) KMT2AHSD17B10MTNR1B
SCHEMBL10003712 0.83 SMO (0.49) USP2TSHRMAPK1ALDH1A1HSD17B10
SCHEMBL10003155 0.82 P2RX7 (0.37) CNR2HTTMEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471789-B9 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-03-25 — — EP disclosed
EP-2471789-B1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2014-09-17 — — EP disclosed
US-8486965-B2 Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-16 — — US disclosed
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-30 — — US disclosed
EP-2471789-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH AKR1C3 1934/4885AKR1C2 1549/4885CYP1A2 1170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback